4,6-Dihydro-5H-pyrrol-benzodiazepin-5-on | 63743-03-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮卓类
• 英文名称: 4,6-Dihydro-5H-pyrrol-benzodiazepin-5-on
• 英文别名: 6,7-Dihydro-5H-pyrrolo[1,2-a][1,5]benzodiazepin-6-one；5,7-dihydropyrrolo[1,2-a][1,5]benzodiazepin-6-one
• CAS: 63743-03-3
• 化学式: C₁₂H₁₀N₂O
• 分子量: 198.224
• InChiKey: QDPUOGCYNFMKFS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  34
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4,6-Dihydro-5H-pyrrol-benzodiazepin-5-on 在 sodium hydroxide 、 dimethyl sulfide borane 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 为溶剂， 生成 6,7-Dihydro-5-(4-amino-2-chlorobenzoyl)-5H-pyrrolo[1,2-a][1,5]benzodiazepine
  参考文献：
  名称：

  Tricyclic diazepine vasopressin antagonists and oxytocin antagonists

  摘要：

  三环二氮杂苯的化学式为：##STR1## 其中A、B、D、E、F、Y和Z在规范中有定义，这些化合物具有抗利尿激素和催产素拮抗活性。

  公开号：

  US05736540A1
• 作为产物：
  描述：

  1-(2-硝基苯基)吡咯 在 双氧水 、 sodium carbonate 作用下， 以 盐酸 、 乙醇 、 二甲基亚砜 为溶剂， 生成 4,6-Dihydro-5H-pyrrol-benzodiazepin-5-on
  参考文献：
  名称：

  Tricyclic diazepine vasopressin antagonists and oxytocin antagonists

  摘要：

  三环二氮杂苯的化学式为：##STR1## 其中A、B、D、E、F、Y和Z在规范中有定义，这些化合物具有抗利尿激素和催产素拮抗活性。

  公开号：

  US05733905A1

文献信息

• Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：——

  公开号：US20020045747A1

  公开（公告）日：2002-04-18

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  公开了抑制β-淀粉样肽释放和/或其合成的化合物，因此可用于治疗阿尔茨海默病。还公开了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物，以及使用这些药物组合物预防性和治疗性治疗阿尔茨海默病的方法。
• Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting B-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：——

  公开号：US20020173504A1

  公开（公告）日：2002-11-21

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  本发明涉及抑制&bgr;-淀粉样肽的释放和/或合成的化合物，因此具有治疗阿尔茨海默病的效用。还公开了包含抑制&bgr;-淀粉样肽释放和/或合成的化合物的药物组合物，以及使用这种药物组合物预防和治疗阿尔茨海默病的方法。
• Tricyclic benzazepine vasopressin antagonists
  申请人：American Cyanamid Company

  公开号：US05610156A1

  公开（公告）日：1997-03-11

  Tricyclic compound of the general Formula I: ##STR1## as defined herein which exhibit antagonist activity at V.sub.1 and/or V.sub.2 receptors and exhibit in vivo vasopressin antagonist activity, methods for using such compounds in treating diseases characterized by excess renal reabsorption of water, and process for preparing such compounds.

  本发明涉及一种三环化合物，其一般式为I：##STR1## 本发明定义的该类化合物在V.sub.1和/或V.sub.2受体上表现出拮抗活性，并在体内表现出抗利尿激素拮抗活性，本发明还涉及使用这种化合物治疗因肾脏过度重吸收水分而引起的疾病的方法，以及制备这种化合物的方法。
• Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-Amyloid peptide release and/or its synthesis by use of such compounds
  申请人：——

  公开号：US20020111343A1

  公开（公告）日：2002-08-15

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  本发明涉及一种抑制β-淀粉样肽释放和/或合成的化合物，因此具有治疗阿尔茨海默病的效用。本发明还涉及包含抑制β-淀粉样肽释放和/或合成的化合物的制药组合物，以及使用这种制药组合物预防和治疗阿尔茨海默病的方法。
• Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：——

  公开号：US20040058900A1

  公开（公告）日：2004-03-25

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  本发明涉及一种抑制β-淀粉样肽的释放和/或合成的化合物，因此在治疗阿尔茨海默病方面具有用途。本发明还涉及包含抑制β-淀粉样肽释放和/或合成的化合物的制药组合物，以及使用这种制药组合物预防和治疗阿尔茨海默病的方法。